Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland - Full Text View

Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (HepCOP)

This study has been completed.

First Received: May 15, 2007 Last Updated: February 13, 2009 History of Changes

Sponsor:	Seidenberg, Arztpraxis A., M.D.
Collaborator:	University of Zurich
Information provided by:	Seidenberg, Arztpraxis A., M.D.
ClinicalTrials.gov Identifier:	NCT00473993

Purpose

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.

Condition
Hepatitis C, Chronic Substance Abuse Treatment Centers Opioid-Related Disorders

Study Type:	Observational
Study Design:	Retrospective
Official Title:	Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung

Resource links provided by NLM:

MedlinePlus related topics: Hepatitis Hepatitis C

U.S. FDA Resources

Further study details as provided by Seidenberg, Arztpraxis A., M.D.:

Study Start Date:	July 2007
Study Completion Date:	December 2007

Detailed Description:

www.seidenberg.ch/hepcop.pdf

Eligibility

Genders Eligible for Study:

Both

Study Population

Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland

Criteria

Inclusion Criteria:

Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473993

Sponsors and Collaborators

Seidenberg, Arztpraxis A., M.D.

University of Zurich

Investigators

Study Director:

André Seidenberg, Dr.med.

research fellow EHAM, University of Zurich

More Information

Additional Information:

download of the protocol of the HepCOP-study This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	HepCOP Zurich
Study First Received:	May 15, 2007
Last Updated:	February 13, 2009
ClinicalTrials.gov Identifier:	NCT00473993 History of Changes
Health Authority:	Switzerland: Ethikkommission

Keywords provided by Seidenberg, Arztpraxis A., M.D.:

Hepatitis C
Opioid Maintenance Treatment
Methadone

Buprenorphine
Heroin
Interferon, pegylated

Additional relevant MeSH terms:

Liver Diseases
RNA Virus Infections
Hepatitis, Chronic
Flaviviridae Infections
Physiological Effects of Drugs
Central Nervous System Depressants
Hepatitis, Viral, Human
Disorders of Environmental Origin
Opioid-Related Disorders
Pharmacologic Actions
Hepatitis
Virus Diseases

Digestive System Diseases
Sensory System Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Peripheral Nervous System Agents
Analgesics
Hepatitis C
Central Nervous System Agents
Hepatitis C, Chronic
Analgesics, Opioid

ClinicalTrials.gov processed this record on November 27, 2009